Cancer Patient Remote Monitoring for Timely Communication Study

The study is designed as a prospective, single-arm observational, mixed-method study. Patients with stage IV NSCLC or inoperable mesothelioma will be included and will be treated with immunotherapy according to current guidelines and standard of care. Patients may receive either a PD1/L1 inhibitor monotherapy or, if indicated, together with a CTLA4 inhibitor. Immunotherapy may be administered alone or together with chemotherapy as per site standard/physician's choice. Patients will be given access to a mobile app. Patients will receive daily questions via the app to assess immune-related adverse events between clinic visits and their well-being.

NCT Number	NCT06623786
Lead Sponsor	Asklepios proresearch Collaborators: Q1.6 B.V., Medical University of Vienna
Conditions	NSCLC Stage IV
Enrollment	100 participants
Start Date	2024-10
Primary Completion	2026-04 (estimated)
Study Completion	2026-04 (estimated)
Updated on ClinicalTrials.gov	2024-10-02